Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Xeris Pharmaceuticals Inc
XERSCurrent price
5.81 USD
+0.44 USD (+8.19%)
Last closed
5.51 USD
Company
www.xerispharma.com
ISIN
US98422E1038
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
502 402 912 USD
Yield for 12 month
+175.36 %
1Y
3Y
5Y
10Y
15Y
XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Address: 180 North LaSalle Street, Chicago, IL, United States, 60601
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.77 USDP/E ratio
–Dividend Yield
–Current Year
+163 914 000 USD
Last Year
+110 248 000 USD
Current Quarter
+54 268 000 USD
Last Quarter
+48 065 000 USD
Current Year
+135 269 000 USD
Last Year
+87 614 000 USD
Current Quarter
+40 675 000 USD
Last Quarter
+37 565 000 USD
Key Figures XERS
1 year
3 years
5 years
10 years
EBITDA
-33 063 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-8.70 %
PEG Ratio
–
Return On Equity TTM
-617.16 %
Wall Street Target Price
4.77 USD
Revenue TTM
187 360 992 USD
Book Value
-0.19 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
12.30 %
Dividend Yield
–
Gross Profit TTM
87 614 000 USD
Earnings per share
-0.43 USD
Diluted Eps TTM
-0.43 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-33.69 %
Dividend Analytics XERS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History XERS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:1
Payout Ratio
–
Last Split Date
06.10.2021
Stock Valuation XERS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3.76
Price Sales TTM
2.68
Enterprise Value EBITDA
-3.36
Price Book MRQ
3.34
Financials XERS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators XERS
For 52 weeks
1.69 USD
3.87 USD
50 Day MA
3.19 USD
Shares Short Prior Month
10 146 898
200 Day MA
2.53 USD
Short Ratio
5.48
Shares Short
9 908 169
Short Percent
6.81 %
BeatStart